The report — which mirrors the format of a children’s book — details the history of PBMs, how their role has changed over the years and how they affect high drug prices.
“[PBMs] morphed from something good and useful into large corporations intent on pursuing profits at the expense of quality patient care,” NCPA writes in the report.
The document includes numerous statistics on drug prices and ends with several policy recommendations to help lower medication prices.
“We’ve created this resource to help our members tell the real story of PBMs,” NCPA CEO B. Douglas Hoey said in a statement. “PBMs say they reduce drug prices and increase patient access, but the facts just don’t bear that out. This new resource sets the record straight.”
To view the full report, click here.
More articles on supply chain:
Critics question FDA nominee’s involvement in Cephalon’s 2006 fentanyl shortage
BD to acquire Bard in $24M deal
FDA targets 14 companies advertising fake cancer products
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
